Adrian Schomburg

Adrian Schomburg has a diverse work experience in the biotechnology and pharmaceutical industry. Adrian is currently the CEO and Founder of Eisbach Bio GmbH, where their main focus is finding cures for tumors that currently have no viable therapeutic options. In 2020, they took on the role of Managing Director Germany at VolitionRx.

Prior to these positions, Adrian worked as a Project Leader at LMU - Ludwig-Maximilians-Universität München in 2018. Adrian also founded and served as CEO of Octamer GmbH from 2018 to 2020.

Adrian has an extensive background at Proteros biostructures GmbH. Adrian held various roles including Chief Technology Officer & Director Target Identification and NEAT Technology from 2015 to 2018, Director Disease Biology from 2014 to 2015, Associate Director from 2012 to 2014, and Research Scientist from 2011 to 2012. In these positions, they successfully managed research projects, delivered preclinical and development candidates, and led a biology group.

Before joining Proteros, Adrian worked as a Research Scientist at Pfizer in 2010 and as a PhD Candidate at Max Planck Institute for Biophysical Chemistry from 2007 to 2010.

Adrian Schomburg obtained an Executive MBA degree from the Technical University of Munich from 2018 to 2022. Adrian also pursued a Certified Private Equity Analyst (CPEA) program at the same university from 2019 to 2020. Prior to their business education, they completed their academic studies in Molecular Biology. Adrian earned their Dr. rer. nat. degree from the International Max Planck Research School from 2005 to 2010, and the University of Göttingen from 2002 to 2010. Additionally, they conducted research at the National Institutes of Health from 2006 to 2007 where they obtained an M.Sc in Molecular Biology.